title: Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.
abstract: Parkinson's disease (PD) affects 10 million people worldwide. Half will develop psychosis, the majority experiencing hallucinations rather than delusions. Emergence of psychosis increases the likelihood of institutionalization and mortality. Where pharmacological treatment is warranted, options are limited. Most currently licensed atypical antipsychotics are ineffective or worsen motor symptoms in people with PD. This review of provides an overview of the current landscape of treatments and the opportunities in emerging research. Clozapine is the only licensed antipsychotic with proven efficacy, although the associated side effects limit its use. With recent advances in understanding the role of serotonin, rational drug design approaches have delivered a novel pharmacological treatment with recently proven efficacy in clinical trials of people with PD and psychosis. Pimavanserin represents an important addition to treatment.
authors.affiliation: Wolfson Centre for Age-Related Diseases, King's College London, London SE1 1UL UK.
authors.forename: Martin
authors.initials: M
authors.lastname: Broadstock
authors.forename: Clive
authors.initials: C
authors.lastname: Ballard
authors.forename: Anne
authors.initials: A
authors.lastname: Corbett
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D012701:Serotonin / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D012701:Serotonin; D003024:Clozapine
keywords: Parkinson’s disease; hallucinations; psychosis; treatment; trials